Wilmer Cutler Pickering Hale and Dorr represented Arbor Biotechnologies in the transaction. Arbor Biotechnologies announced a strategic partnership with 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT). As part of...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Voyager Therapeutics, Inc. in the transaction. Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced a strategic collaboration and capsid license agreement with...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Wonder Group in the transaction, and Wilmer Cutler Pickering Hale and Dorr represented Blue Apron Holdings. Wonder Group (“Wonder”) announced that it has...
You must be a Standard 1 Year member to access this content.
WilmerHale represented Blue Apron in the transaction. Blue Apron (NYSE: APRN), an American ingredient-and-recipe meal kit company, announced the signing and closing of a transaction with...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Voyager Therapeutics on the deal. Voyager Therapeutics announced that it entered into a strategic collaboration agreement with Neurocrine Biosciences...
You must be a Standard 1 Year member to access this content.
WilmerHale advised Voyager Therapeutics on the deal. Voyager Therapeutics, a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, announced it entered into...
You must be a Standard 1 Year member to access this content.
